Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk

Dow Jones

01/14

1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. "Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission," analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 13, 2026 14:16 ET (19:16 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603632297"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603632297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603632297?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603632297","market":"fut","top_or_hot":-1,"title":"Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1416 ET - <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 14:16 ET (19:16 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 03:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1416 ET - <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 14:16 ET (19:16 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603632297","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603632297","pubTimestamp":1768331760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically  that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IRON":"Disc Medicine","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"Disc Medicine表示FDA对Bitopertin的参与仍然富有成效——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":1.5},"content_text":"1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 14:16 ET (19:16 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}